HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
View on Grants.gov ↗ Sign in to save
- Type
- Grant
- Notice type
- CA
- Agency
- National Institutes of Health
- Sub-agency
- HHS-NIH11
- Solicitation #
- RFA-NS-27-007
- Posted
- Jun 16, 2026
- Response due
- Feb 20, 2029
- Archive date
- Apr 21, 2029
- CFDA / Assistance listing
- 93.213,93.233,93.273,93.279,93.395,93.837,93.838,93.839,93.840,93.846,93.853,93.865,93.866,93.867
- Total program funding
- $11,000,000
- Contact
- PTDP@ninds.nih.gov
- Source
- Grants.gov
Description
The purpose of this Notice of Funding Opportunity (NOFO) is to support the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics for the treatment of pain. The goal of the program is to accelerate the advancement of promising early-stage therapeutic candidates and facilitate their readiness for Phase II clinical trials. Applicants must have a promising small molecule or biologic lead candidate for optimization, a strong biological rationale for the proposed approach, and established assays to guide the optimization process. The scope of the program includes lead optimization, early-stage development activities, IND-enabling studies, development of pharmacodynamic and/or target engagement biomarkers, preparation and submission of an Investigational New Drug (IND) application, and Phase I clinical testing. This is a milestone-driven, phased cooperative agreement program that involves active participation by NIH program staff in project planning and ongoing monitoring of research progress.